Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04083950 · ClinicalTrials.gov registry record · Early Phase 1
Induction of Gut Permeability by an Oral Vaccine
A Early Phase 1 study of Inflammation and Vaccine, sponsored by USDA, Western Human Nutrition Research Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04083950: Active Early Phase 1 study of Inflammation and Vaccine, sponsored by USDA, Western Human Nutrition Research Center.
NCT04083950 is a Early Phase 1 study of Inflammation and Vaccine that is active but no longer recruiting, run by USDA, Western Human Nutrition Research Center. The registered enrollment target is 10 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04083950, a Early Phase 1 study of Inflammation and Vaccine, is active but no longer recruiting, sponsored by USDA, Western Human Nutrition Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.
Primary Outcome
Measurement of sugar (lactulose, D-mannitol, and sucralose) excretion in urine.
Conditions Studied
Interventions
- BIOLOGICAL Vivotif Typhoid Oral Vaccine
- DRUG Aspirin (Positive Control)
Study Locations (1)
California
- USDA, ARS, Western Human Nutrition Research Center - Davis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-09-30 |
| Phase | Early Phase 1 |
What the registry record for NCT04083950 still lists
NCT04083950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Vivotif Typhoid Oral Vaccine is the first listed.
NCT04083950 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04083950 about?
NCT04083950 is a clinical study titled "Induction of Gut Permeability by an Oral Vaccine". This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.
What is the current status of trial NCT04083950?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-12-04. Estimated completion is 2026-09-30.
What conditions does trial NCT04083950 study?
This clinical trial studies the following conditions: Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever.
What interventions are being tested in trial NCT04083950?
The interventions under investigation include: Vivotif Typhoid Oral Vaccine (BIOLOGICAL), Aspirin (Positive Control) (DRUG).
Who is sponsoring clinical trial NCT04083950?
This trial is sponsored by USDA, Western Human Nutrition Research Center, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04083950 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04083950's enrollment target sits among peer trials
10 128th of 132 higher than 2 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
RECRUITING · Early Phase 1
-
Sleep and Inflammatory Resolution Pathway
ACTIVE NOT RECRUITING · Early Phase 1
-
Effect of High-Legume Diet on Colorectal Cancer Risk
COMPLETED · Early Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI